IMAGINT

HER Imaging and Molecular Interaction Mapping in Breast Cancer

 Coordinatore UNIVERSITY COLLEGE LONDON 

 Organization address address: GOWER STREET
city: LONDON
postcode: WC1E 6BT

contact info
Titolo: Ms.
Nome: Greta
Cognome: Borg-Carbott
Email: send email
Telefono: +44 20 3108 3033
Fax: +44 20 7813 2849

 Nazionalità Coordinatore United Kingdom [UK]
 Totale costo 7˙411˙567 €
 EC contributo 5˙683˙589 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2010-two-stage
 Funding Scheme CP-FP
 Anno di inizio 2011
 Periodo (anno-mese-giorno) 2011-05-01   -   2015-04-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    UNIVERSITY COLLEGE LONDON

 Organization address address: GOWER STREET
city: LONDON
postcode: WC1E 6BT

contact info
Titolo: Ms.
Nome: Greta
Cognome: Borg-Carbott
Email: send email
Telefono: +44 20 3108 3033
Fax: +44 20 7813 2849

UK (LONDON) coordinator 1˙678˙111.00
2    UNIVERSITAET ZUERICH

 Organization address address: Raemistrasse 71
city: ZURICH
postcode: 8006

contact info
Titolo: Prof.
Nome: Andreas
Cognome: Plueckthun
Email: send email
Telefono: +41 44 6355570
Fax: +41 44 6355712

CH (ZURICH) participant 1˙057˙073.00
3    KING'S COLLEGE LONDON

 Organization address address: Strand
city: LONDON
postcode: WC2R 2LS

contact info
Titolo: Dr.
Nome: Tony
Cognome: Ng
Email: send email
Telefono: +44 0207 848 8056
Fax: +44 0207 848 6220

UK (LONDON) participant 635˙749.00
4    UPPSALA UNIVERSITET

 Organization address address: SANKT OLOFSGATAN 10 B
city: UPPSALA
postcode: 751 05

contact info
Titolo: Dr.
Nome: Anders
Cognome: Alderborn
Email: send email
Telefono: 46184712577

SE (UPPSALA) participant 545˙736.00
5    TOPOSNOMOS LTD

 Organization address address: CALDERVALE ROAD THE PICASSO
city: WAKEFIELD
postcode: WF1 5PF

contact info
Titolo: Dr.
Nome: Walter
Cognome: Schubert
Email: send email
Telefono: +49 391 6117175
Fax: +49 3929228040

UK (WAKEFIELD) participant 435˙454.75
6    Innovative Technologies in Biological Systems

 Organization address city: Derio
postcode: 48160

contact info
Titolo: Dr.
Nome: Salado
Cognome: Clarisa
Email: send email
Telefono: 34944005355
Fax: 34946579925

ES (Derio) participant 417˙600.00
7    MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.

 Organization address address: Hofgartenstrasse 8
city: MUENCHEN
postcode: 80539

contact info
Titolo: Mr.
Nome: Manfred
Cognome: Messerschmidt
Email: send email
Telefono: +49 551 2011221
Fax: +49 551 2011331

DE (MUENCHEN) participant 394˙300.00
8    FIRALIS S.A.S.

 Organization address address: Rue du Fort
city: Huningue
postcode: 68330

contact info
Titolo: Prof.
Nome: Hüseyin
Cognome: Firat
Email: send email
Telefono: +33 981 654 553
Fax: +33 981 708 433

FR (Huningue) participant 326˙194.00
9    NOVAMEN SAS

 Organization address city: LYON
postcode: 69002

contact info
Titolo: Dr.
Nome: Marie-Laure
Cognome: Muiras
Email: send email
Telefono: +33 4 78 92 40 00
Fax: +33 4 78 92 40 01

FR (LYON) participant 193˙372.00
10    ACIES Consulting Group SAS

 Organization address city: LYON
postcode: 69002

contact info
Titolo: Dr.
Nome: Marie-Laure
Cognome: Muiras
Email: send email
Telefono: +33 4 78 92 40 00
Fax: +33 4 78 92 40 01

FR (LYON) participant 0.00
11    MEDIPOLIS GMP OY

 Organization address address: Kiviharjuntie
city: OULU
postcode: 90220

contact info
Titolo: Dr.
Nome: Ashesh
Cognome: Kumar
Email: send email
Telefono: 358400000000
Fax: +358 207 545 879

FI (OULU) participant 0.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

darpins    trial    anti    complexes    dye    analysed    tools    determine    imaging    outcome    interactions    cancer    egfr    proteins    data    biomarkers    her    technologies    breast    clinical    rna    single    protein   

 Obiettivo del progetto (Objective)

'The aim is to develop tools for imaging and characterising protein/protein and protein/RNA interactions in cancer using Designed Ankyrin Repeat Proteins (DARPins). DARPins are small, ultrahighly stable, antibody-like proteins that bind specific targets with high affinity in monovalent form and are readily engineered for site-specific chemical modification. The exemplar protein family will be EGFR, with focus on HER2-mediated processes in cancer. 1. EGFR-reactive DARPins will be used to characterise HER2 homo- and hetero-dimers using 4 novel technologies: Single Molecule Fluorescence, Proximity Ligation, super-resolution microscopy and FRET/FLIM. The collected data will be analysed with information on clinical outcome to determine which HER2 interactions are associated with resistance to HER2 targeted treatments. 2. Protein/RNA complexes will be isolated and characterised. These complexes may be new biomarkers for breast cancer and their characterisation is aimed at elucidating mechanisms of transcriptional regulation in response to anti-HER2 treatment. 3. Protein networks associated with EGFR signalling by imaging clusters of at 50-100 different proteins in a single cell or tissue section. This will be achieved with a robot, using large dye-conjugated tag libraries, and automatically bleaching a dye after imaging and re-labelling with another. 4. Whole body imaging (Phase I/II) clinical trial will use radiolabelled anti-HER2 DARPins to improve specificity and sensitivity of quantitative PET/SPECT/CT. The trial aims to image HER2 positive metastatic cancer and provide circulating tumour cells (CTCs) and biopsies for more detailed analysis. 5. Multivariate data obtained by the new technologies will be analysed with a range of bioinformatic tools, including artificial neural network methods, to determine novel biomarkers that aim to classify breast cancer patients at an individualised level. The outcome is to increase the tool panel of clinicians.'

Altri progetti dello stesso programma (FP7-HEALTH)

MON4STRAT (2014)

"Therapeutic Beta-Lactam Monitoring for Stratified Treatment of hospital-acquired pneumonia, improved dose-dependent efficacy, decreased treatment duration, and prevention of emergence of resistance"

Read More  

AMASA (2010)

Accessing Medicines in Africa and South Asia

Read More  

ARTFORCE (2011)

Adaptive and innovative Radiation Treatment FOR improving Cancer patients treatment outcomE

Read More